U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H23NO2S
Molecular Weight 281.4153
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OSU-6162

SMILES

CCCN1CCC[C@]([H])(C1)c2cccc(c2)S(=O)(=O)C

InChI

InChIKey=GZVBVBMMNFIXGE-CQSZACIVSA-N
InChI=1S/C15H23NO2S/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3/t14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H23NO2S
Molecular Weight 281.4153
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

PNU-96391A (known as OSU6162) is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. OSU6162 seem to act as stabilizers not only on dopaminergic, but also on serotonergic brain signaling (partial agonist on 5-HT2A receptor). OSU6162 in a phase II European clinical trial in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. One of the isomer of OSU 6162, has promise for treating Parkinson's disease, Huntington's disease and schizophrenia, but both enantiomers of OSU 6162 had dual effects on behavior, stimulating locomotor activity in 'low activity' animals and inhibiting locomotor activity in 'high activity' animals.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
447 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PubMed

PubMed

TitleDatePubMed
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
2001 May
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
2006 Aug
II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.
2011 Nov
The Effects of (-)-OSU6162 on Chronic Fatigue in Patients With Traumatic Brain Injury: A Randomized Controlled Trial.
2017 Mar/Apr
Patents

Sample Use Guides

OSU6162 of 30-60 mg/day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:15:06 UTC 2021
Edited
by admin
on Sat Jun 26 12:15:06 UTC 2021
Record UNII
0D21EQAQQA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OSU-6162
Code English
PNU-96391
Code English
(-)-OSU 6162
Code English
PIPERIDINE, 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYL-, (3S)-
Systematic Name English
Code System Code Type Description
FDA UNII
0D21EQAQQA
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
CAS
146798-66-5
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
PUBCHEM
9795741
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
WIKIPEDIA
OSU-6162
Created by admin on Sat Jun 26 12:15:06 UTC 2021 , Edited by admin on Sat Jun 26 12:15:06 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET->PARTIAL AGONIST
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET->PARTIAL AGONIST
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
ACTIVE MOIETY